Xylooligosaccharides Alleviate Inflammatory Dermatoses and Related Depression-Like Behaviors in Atopic Dermatitis Mice Induced by 2,4-Dinitrofluorobenzene

Objective:To investigate the influence of xylooligosaccharides on skin inflammation,behavioral characteristics,neurotransmitters,and gut flora in a mouse model of atopic dermatitis(AD)induced by 2,4-dinitrofluorobenzene(DNFB).Methods:The AD mouse model was created by administration of DNFB for 14 consecutive days.The scoring atopic dermatitis index,enzyme-linked immunosorbent assay(ELISA),histopathology,and immunohistochemical analyses were used to assess inflammation and depression-like behaviors.Furthermore,high-throughput 16S rRNA gene sequencing was used to determine the composition of fecal microbiota.Results:Xylooligosaccharides treatment reduced the number of scratches and skin thickness,mast cell infiltration and the levels of immunoglobulin(Ig)E and T-helper cytokines compared with the AD model group.Meanwhile,xylooligosaccharides treatment reduced the immobility time of mice in the forced swimming test and increased the total movement distance and movement distance in the center area in the open-field test.Furthermore,5-hydroxytryptamine and dopamine expression in the brain was increased following xylooligosaccharides treatment.Using network pharmacology,Gene Ontology analysis showed that the targets were mainly enriched in phosphatase binding and the regulation of leukocyte differentiation,which ameliorated AD mainly through the hypoxia inducible factor-1 and phosphatidylinositide 3-kinase-protein kinase B pathways.16S rRNA gene sequencing,diversity indices,and gut microbial taxonomic composition analysis showed DNFB-induced changes in intestinal microbiota diversity in AD mice.Comparative analysis indicated that xylooligosaccharides intake improved the gut microbiome by dramatically enhancing the concentration of Lactobacillus while decreasing the concentration of Bacteroides in mice.Conclusion:Xylooligosaccharides reduce inflammatory dermatosis and related depression-like behaviors via regulating intestinal homeostasis,having medicinal value as a nutritional and functional ingredient.

Outcome of Nurses with Occupational Dermatitis

Background: Occupational dermatitis is considered as the second most common occupational disease. It accounts for 25% of all lost workdays. Several international studies reported a prevalence of occupational dermatitis in healthcare workers between 17% and 55%. This study aims to identify factors that affect the professional outcome of nurses suffering from occupational dermatitis. Methods: This was a multicenter cross-sectional study concerning nurses declared having occupational dermatitis in the central region of Tunisia. A synoptic sheet related to socio-professional and administrative data was completed. A self-administered Questionnaire going over medical and occupational characteristics was completed during a direct interview. Results: The study involved forty nurses working in four public hospitals in the center of Tunisia. Only 37 workers were included in the study. A professional reclassification was introduced among 19 workers (51% of study population). Work-station adaptation was requested in 14 cases (38%). Exposure to allergens in the workplace was eliminated in 20 cases. Two study participants were transferred to other departments (5.4%) and three people retired (8.1%). A statistically significant association was found between professional reclassification and a history of allergic manifestations (p = 0.003). Similarly, a significant association was found between professional reclassification and the allergic agent (p = 0.014). Workstation layout was significantly associated with a history of allergic manifestations (p = 0.039), the palm hand location (p = 0.04), professional eviction (p Conclusion: This study identified the main factors influencing the occupational outcome of nurses suffering from occupational dermatitis. This outcome depended on a history of atopy (especially allergic rhinitis) and sensitization to allergens (thiuram mix).

Preparation of anti-canine interleukin-31 receptor alpha polyclonal antibody and evaluation of its therapeutic efect in canine atopic dermatitis

Canine atopic dermatitis(CAD)is a prevalent genetically susceptible infammatory and pruritic allergic skin condition afecting not only the health of dogs but also the quality of life of their owners.Interleukin-31(IL-31)and interleukin-31 receptor alpha(IL-31RA)are essential for the development of pruritus in primates and mice.Hence,it is expected that inhibiting IL-31RA will be an efective approach to alleviate pruritus.The purpose of the study was to produce anti-canine IL-31RA polyclonal antibodies(anti-IL-31RA pAbs)and evaluate their efcacy in inhibiting house dust mite(HDM)-evoked pruritic responses.Dogs were immunized with antigens formed by IL-31RA recombinant short peptides coupled to BSA to produce anti-IL-31RA pAbs.The CAD model was developed by using HDM allergen stimulation,and the efects of IL-31RA pAbs on the reduction of pruritus in CAD model dogs were examined.The Canine Atopic Dermatitis Extent and Severity Index(CADESI)-4 and pruritus Visual Analog Scale(pVAS)were utilized to evaluate pruritic responses,and skin tissue samples were collected from the inguinal area for pathological assessment of skin infammatory cell infltration.The results showed that anti-IL-31RA pAbs with high titers(1:128,000)and specifcity were efectively produced.In the CAD model group,the severity of skin damage,pruritus score,infammatory cell infltration and level of infammatory factors were considerably elevated.Anti-IL-31RA pAbs relieved pruritic behavior and dermatitis in dogs compared to placebo-treated dogs.In conclusion,anti-IL-31RA pAbs efectively suppressed CAD in vivo and are anticipated to be an efective novel treatment for pruritic skin disorders such as CAD.

Blue Cap Is Effective and Safe for the Treatment of Atopic Dermatitis in Children

Background: Atopic dermatitis (AD) is the most common inflammatory skin disease in children. Treatment of AD is based on skin barrier repair and reduction of inflammation. We analyzed the efficacy and safety of activated piroctone olamine (APO)—Blue Cap—in children with AD. Materials and Methods: An open-label interventional clinical study was carried out at three clinical centers in Serbia. A total of 58 patients with AD, aged between 3 and 18 years were included and treated with Blue Cap Foam (100 ml;CATALYSIS S.L. Madrid)—Activated Piroctone Olamine—applied twice a day in the affected areas with eczema for 30 days and final assessment at 45 days from baseline. Photographic documentation, clinical evaluation, therapy effectiveness and safety questionnaires were assessed at baseline, 15, 30 and 45 days. Results: Our results demonstrated a significant reduction in signs (erythema, scaling, infiltration, excoriations, xerosis) and symptoms (pruritus) at weeks 2 and 4 of the study. At the end of the study, most patients had moderate (28.6%) to great (62.5%) disappearance of manifestations and moderate (25%) to great (71.4%) skin quality improvement. The effect and tolerability of the therapy were evaluated as very good in 66.1 % and 67.9% and good in about 14.3% and 17.9%, assessed by the investigator and patient, respectively. Three patients experienced a burning sensation at the beginning of the study, the side-effects were resolved as the patients continued applying the foam. After two weeks of cessation of the investigated foam, a significant percentage of patients experienced worsening in the final assessment done by the investigator as well as the participant. In the final assessment, a significantly high percentage (57.1%) of patients had a total reduction of manifestation, and a significant number of participants considered the applied product as treatment success, assessed by the investigator (62.5%) as well as the participants (66.4%). Conclusions: Blue Cap is effective and safe in children with AD, although further large-scale randomized controlled trials should confirm our study findings.

Psychosocial and Socioeconomic Barriers to Treatment Adherence in Pediatric Atopic Dermatitis

Research Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition in children that significantly impacts physical health and quality of life. Adherence to treatment regimens is crucial for effective disease management but is often hindered by various psychosocial and socioeconomic barriers. Parental mental health issues, family dynamics, financial constraints, and limited access to specialized care contribute to inconsistent treatment adherence, exacerbating the condition. Purpose/Aim: The aim of this study is to explore the multifaceted barriers to treatment adherence in children with AD and evaluate the effectiveness of current interventions targeting these challenges. The study seeks to identify strategies that can improve adherence and health outcomes by addressing psychosocial and socioeconomic factors. Method: The method involves a comprehensive review of existing literature on the impact of psychosocial and socioeconomic factors on treatment adherence in children with AD. The study also examines various interventions designed to address these barriers, including community support programs, family-centered interventions, financial aid, integrated care models, and telehealth solutions. Results: Results indicate that psychosocial barriers, such as parental anxiety and depression, significantly hinder effective disease management. Family dynamics, including poor communication and single-parent households, complicate adherence efforts. Socioeconomic factors, such as financial constraints and limited healthcare access, further impede adherence. Interventions that address these barriers show promise in improving treatment adherence and health outcomes. Community support programs and family-centered interventions enhance parental mental health and family communication. Financial aid programs and integrated care models help mitigate economic and logistical challenges. Telehealth solutions improve access to specialized care, particularly in underserved areas. Conclusion: The study concludes that a holistic approach integrating medical treatment with psychosocial and socioeconomic support is essential for managing pediatric AD effectively. Policy recommendations include increased funding for community support programs, expanded telehealth services, and the integration of social services with medical care. Addressing these barriers comprehensively can enhance treatment adherence and improve the quality of life for children with AD. Further research should focus on long-term outcomes and diverse populations to refine these interventions and ensure they meet the needs of all affected children.

Acupoint catgut-embedding therapy ameliorates DNCB-induced atopic dermatitis in BALB/c mice by regulating Th2 type immune response and reducing infiltration of CD4^(+)and CD8^(+)cells

Background:This study aimed to assess how acupoint catgut-embedding therapy influences Th2-type immune response and the infiltration of CD4^(+)and CD8^(+)cells in DNCB-induced atopic dermatitis in BALB/c mice.It also conducted an initial examination of the underlying molecular mechanisms.Methods:Seventy-two mice were randomly divided into four groups:normal control,DNCB-induced atopic dermatitis model(AD),AD with acupoint catgut-embedding treatment(ADA),and AD with sham-acupoint catgut-embedding treatment.After DNCB challenge to induce AD,the ADA group received acupoint catgut-embedding therapy treatment at Zusanli(ST 36)and Quchi(LI 11)acupoints every other week from day 8.Mice in the AD with sham-acupoint catgut-embedding treatment group underwent the same procedure as the ADA group but without catgut implantation.Severity was assessed using SCORAD on treatment days 1,10,and 20.On day 18,nine mice per group were euthanized,and the remaining on day 28.Histopathological changes were observed using hematoxylin-eosin and immunohistochemistry staining.TNF-α,IL-4,IL-6,and IL-13 levels were analyzed by ELISA,and GATA3 and STAT6 protein levels by western blot.Results:After 20 days of acupoint catgut-embedding therapy treatment,mice showed reduced dermatitis scores compared to DNCB-induced AD-like mice.Significant decreases occurred in serum IL-4,IL-6,IL-13,and TNF-αlevels.Skin analysis revealed marked reductions in CD4^(+)and CD8^(+)cell infiltration,as well as GATA3 and STAT6 protein levels.Conclusion:Acupoint catgut-embedding therapy may effectively alleviate atopic dermatitis by suppressing Th2 immune responses via the STAT6-GATA3 pathway and reducing CD4^(+)and CD8^(+)T cell infiltration in skin lesions.

Preprocessing and Efficacy Analysis of Comprehensive Anti-Inflammatory Treatment for Lymphedema in Patients with Irritating Contact Dermatitis

Objective: To explore the pre-treatment and efficacy analysis of comprehensive anti-inflammatory treatment for lymphedema in patients with irritating contact dermatitis. Method: Convenience sampling method was used to observe the skin of 160 patients with upper limb lymphedema admitted to the lymphedema outpatient department of our hospital. They were divided into an observation group (80 cases) and a control group (80 cases), and both groups received a course of comprehensive anti-inflammatory treatment (20 treatments). The control group received routine skin care;On the basis of the control group, the observation group received pre-treatment of the affected limb skin: Laofuzi herbal ointment was applied externally to the prone areas of irritating contact dermatitis (such as the upper arm, inner forearm, and cubital fossa). Result: The incidence of irritating contact dermatitis in the observation group was significantly lower than that in the control group (P 0.05). Patients in the observation group felt significantly better in terms of comfort, skin moisture, and itching relief after being wrapped with low elasticity bandages than those in the control group (P Conclusion: Preventive treatment can effectively reduce the incidence of irritating contact dermatitis, prolong the time of stress treatment, thereby increasing efficacy and improving patient compliance.

Advancements in the application of natural extracts for atopic dermatitis treatment

Atopic dermatitis,a common chronic inflammatory skin disease,has an unclear etiology and may involve multiple factors such as genetic predisposition,immune abnormalities,and impaired skin barrier function.Currently,there is no specific medication available for the complete cure of atopic dermatitis.The current treatment approaches mainly focus on symptom relief and control rather than curative treatment.Some commonly used medications for atopic dermatitis,such as topical corticosteroids and immunosuppressants,may have certain adverse reactions and side effects.This review summarizes the research progress on natural extracts in the treatment of atopic dermatitis,aiming to provide a foundation for the development of safe and side-effectfree medications.

Correlation Analysis Between Children with Atopic Dermatitis and Asthma and Factors Affecting Intestinal Flora

Objective:In order to reveal the potential association between intestinal flora and atopic dermatitis with asthma,the study compares the changes in intestinal flora before and after treatment with antibiotics in children and explores the risk factors for the disease development in children.The differences between asthma-controlled children and healthy children were also analyzed to investigate whether there was a correlation between the level of control and intestinal flora in asthmatic children.Methods:367 children with atopic dermatitis and asthma were selected,and the control group was healthy children who did not have other skin diseases.Fecal samples were collected from healthy children and children with asthma,and the intestinal flora was tested at Beijing Nebula Medical Testing Laboratory Co.At the same time,50 children were selected according to the inclusion and exclusion criteria to take amide antibiotics during hospitalization,and stool samples were collected before and after taking antibiotics.Results:The proportion of Gram-positive cocci increased and the proportion of Gram-positive bacilli decreased after the administration of antibiotics in children with atopic dermatitis and asthma(P<0.05),and no significant difference was shown in the gender and age of the children(P>0.05).The proportion of family history of atopic dermatitis with asthma was higher in the experimental group(P<0.05).Conclusion:The use of antibiotics in children with atopic dermatitis with asthma showed a positive correlation with changes in intestinal flora.The use of antibiotics may lead to changes in intestinal flora and increase the risk of atopic dermatitis with asthma.Antibiotic use in infancy and childhood is also recognized as a risk factor for atopic dermatitis with asthma.Therefore,the use of antibiotics should be minimized in preventing and treating atopic dermatitis with asthma.

Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab:Four case reports

BACKGROUND Lichen amyloidosis(LA)is a chronic,severely pruritic skin disease,which is the most common form of primary cutaneous amyloidosis.The treatment of LA has been considered to be difficult.LA may be associated with atopic dermatitis(AD),and in this setting,the treatment options may be more limited.Herein,we report four cases of LA associated with AD successfully treated by dupilumab.CASE SUMMARY In this article,we describe four cases of patients who presented with recurrent skin rash accompanied by severe generalized intractable pruritus,diagnosed with refractory LA coexisting with chronic AD.Previous treatments had not produced any apparent improvement.Thus,we administered dupilumab injection subcutaneously at a dose of 600 mg for the first time and 300 mg every 2 wk thereafter.Their lesions all markedly improved.CONCLUSION Dupilumab may be a new useful treatment for LA coexisting with AD.

Dupilumab for treatment of severe atopic dermatitis accompanied by lichenoid amyloidosis in adults:Two case reports

BACKGROUND Lichenoid amyloidosis(LA)is a subtype of primary cutaneous amyloidosis characterized by persistent multiple groups of hyperkeratotic papules,usually on the lower leg,back,forearm,or thigh.LA may be associated with several skin diseases,including atopic dermatitis(AD).The treatment of LA is considered to be difficult.However,as there is some overlap in the etiopathogenesis of LA and AD,AD treatment may also be effective for LA.CASE SUMMARY Case 1:A 70-year-old man was diagnosed with severe AD with LA based on large dark erythema and papules on the trunk and buttocks and dense hemispherical millet-shaped papules with pruritus on the extensor side of the lower limbs.He had a long history of the disease(8 years),with repeated and polymorphic skin lesions.Given the poor efficacy of traditional treatments,this patient was recommended to receive dupilumab treatment.At the initial stage,300 mg was injected subcutaneously every 2 wk.After 28 wk,the drug interval was extended to 1 mo due to the pandemic.Follow-up observations revealed that the patient reached an Eczema Area Severity Index of 90(skin lesions improved by 90%compared with the baseline)by the end of the study.Moreover,Investigator's Global Assessment score was 1,and scoring atopic dermatitis index and numeric rating scale improved by 97.7%and 87.5%compared with the baseline,respectively,with LA skin lesions having largely subsided.Case 2:A 30-year-old woman was diagnosed with severe AD with LA,due to dense and substantial papules on the dorsal hands similar to changes in cutaneous amyloidosis,and erythema and papules scattered on limbs and trunk with pruritus,present for 25 years.After 16 wk of dupilumab treatment,she stopped,and skin lesions completely subsided,without recurrence since the last follow-up.CONCLUSION Dupilumab shows rational efficacy and safety in the treatment of severe AD with LA,in addition to benefits in the quality of life of the patients.

Ocular manifestations of children with atopic dermatitis in Saudi Arabia

AIM:To examine the incidence of ocular abnormalities in children with atopic dermatitis(AD)in Saudi Arabia and its association with the severity of AD.METHODS:This is a cross-sectional study on 50 children with AD who were between 5 and 16 years of age.The severity of AD was evaluated using the SCORing Atopic Dermatitis(SCORAD)index.All the children underwent slit lamp exams,visual acuity assessment,intraocular pressure measurement,and corneal topography.The children were considered to have an ophthalmic abnormality if one or more of the following signs were present:glaucoma,keratoconus suspicion,in addition to lid,conjunctival,corneal,lenticular,or retinal abnormalities.RESULTS:Based on the SCORAD severity index,14%of children had mild AD(7/50),38%had moderate AD(19/50),and nearly half had severe AD.More than half the children exhibited facial involvement,and half had peri-orbital signs.The mean SCORAD index was 35.75.The mean age was 10.48±3.6y,and the cohort showed a slight male predominance(54%males).Both eyes of the 50 children in the cohort were studied.Based on the ocular examinations,92%of the patients showed ocular abnormalities:lid abnormalities(27/50)followed by keratitis(22/50).Four patients had moderate risk for keratoconus in one eye and eight patients were suspected to have keratoconus.However,SCORAD severity index was not associated with age,sex,or the number or presence of ophthalmic abnormalities.CONCLUSION:This is the first study in Saudi Arabia to evaluate the prevalence of ocular manifestations in children with AD.The results indicate that the majority of children with AD have ocular abnormalities that mainly include lid abnormalities.Based on these findings,larger scale studies are needed to affirm whether regular screening for ophthalmic abnormalities would be beneficial for children with AD in terms of early intervention and prevention of sight-threatening complications.

Investigation of possible relationship between atopic dermatitis and salivary biomarkers,stress,and sleep disorders

Atopic dermatitis(AD)is a chronic,relapsing,multifactorial inflammatory disease with genetic,environmental,and immunological characteristics.The quality of life and sleep of patients and their families are affected by AD,which triggers stress,described as one of the factors that worsens AD.Salivary biomarkers such as cortisol,alpha-amylase,chromogranin A,and melatonin have been associated with stress and sleep disturbances.Therefore,the evaluation of stress and sleep disorders using salivary biomarkers in AD patients is important.This review aims to describe the possible relationship between atopic dermatitis and stress,sleep disorders,and salivary biomarkers,seeking to contribute to better understanding and clinical management of AD.This descriptive study is characterized as a narrative literature review.A literature search was conducted of studies published in English and Portuguese between January 2012 and October 2022 that are available in electronic media from various databases,such as Scientific Electronic Library Online,Latin American and Caribbean Literature on Health Sciences,and PubMed.AD is associated with different degrees of impact on the lives of individuals who present with the disease.Psychological stress may induce changes in saliva composition and worsen AD;at the same time,the severity of the disease may be associated with emotional impact.Further studies are needed to assess and correlate AD severity,stress,and sleep disturbances with salivary biomarkers in order to better understand this association.

苦参碱对特应性皮炎炎症、氧化应激和伤口愈合的影响

目的评估苦参碱对体外特应性皮炎(AD)模型中HaCaT角质形成细胞的炎症、氧化和迁移反应及伤口愈合的影响。方法采用MTT法评估苦参碱的细胞毒性,依据实验结果,将HaCaT细胞分为对照组,模型组,苦参碱0.05、0.1和0.2 mmol/L组,模型组采用10μg/L肿瘤坏死因子-α(TNF-α)/干扰素-γ(IFN-γ)刺激HaCaT细胞24 h,苦参碱0.05、0.1和0.2 mmol/L组分别用相应浓度的苦参碱预处理细胞1 h,然后用10μg/L TNF-α/IFN-γ刺激24 h。酶联免疫吸附试验(ELISA)法测定白细胞介素(IL)-6、IL-8和IL-1β和胸腺和活化调节趋化因子(TARC)、巨噬细胞衍生趋化因子(MDC)、调节活化正常T细胞表达和分泌的因子(RANTES)的水平;实时荧光定量PCR检测抗氧化基因表达水平;划痕愈合实验分析细胞迁移;免疫组织化学分析核因子(NF)-κB p65的核易位;Western blot检测p38、细胞外调节蛋白激酶(ERK)和p65蛋白的磷酸化水平。结果与模型组比较,苦参碱0.1和0.2 mmol/L组降低IL-6、IL-1β、IL-8和趋化因子的表达,增强超氧化物歧化酶(SOD)1、SOD2、过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GPx)的表达,并促进划痕愈合率(P<0.05)。此外,苦参碱0.1和0.2 mmol/L可抑制p38、ERK和p65蛋白的磷酸化及p65的核易位。结论苦参碱具有抗炎和抗氧化特性,并刺激角质形成细胞AD模型的伤口闭合。

Curative Effect of 30% Supramolecular Salicylic Acid Combined with Yufa Spray Dressing on Moderate to Severe Scalp Seborrheic Dermatitis

Objective:To observe the clinical efficacy of 30%supramolecular salicylic acid combined with Yufa spray dressing in the treatment of moderate to severe seborrheic dermatitis(seborrheic dermatitis of the scalp,SDS).Methods:From January 2020 to December 2021,150 patients with SDS,who were treated in the Dermatology Clinic of the First Affiliated Hospital of Xi’an Medical University,were randomly divided into two groups,a treatment group and a control group,with 75 cases in each group.The treatment group was given 30%supramolecular salicylic acid combined with Yufa spray dressing on the basis of external medicine given to the control group,while the control group was given oral medicine combined with external medicine.Results:The difference in scores of erythema,scales,pruritus,and folliculitis of the treatment group before and after treatment was significant(P<0.01),indicating that supramolecular salicylic acid combined with Yufa spray dressing can relieve the symptoms of SDS.The difference in scores of erythema of the control group before and after treatment was significant as well(P<0.05),indicating that traditional antibiotics are also effective in treating SDS;however,there was no significant difference(P>0.05)in the scores of other signs and symptoms,such as scales,pruritus,and folliculitis,before and after treatment,indicating that traditional antibiotics have no obvious curative effect on SDS.After 12 weeks of treatment,the improvement in erythema,scaling,and folliculitis was significantly greater in the treatment group compared with the control group(P<0.05).Curative effect comparison showed that the total effective rate of the treatment group was 80.00%,compared with 25.67%of the control group,and the difference was statistically significant(P<0.05).Conclusion:30%supramolecular salicylic acid combined with Yufa spray dressing can significantly improve the therapeutic effect in moderate to severe SDS;the recurrence rate is lower,the course of treatment is shorted,and patients generally feel better;thus,it is a new option for the treatment of dermatitis.

健脾祛风汤联合皮炎洗剂治疗特应性皮炎疗效研究

目的:研究健脾祛风汤联合皮炎洗剂治疗特应性皮炎的效果及对免疫球蛋白E(IgE)和白介素-4(IL-4)的影响。方法:收集120例特应性皮炎患者临床资料,并开展回顾性对比研究。观察组60例,行健脾祛风汤联合皮炎洗剂;对照组60例,行皮炎洗剂干预。比较两组患者治疗效果,记录两组患者治疗前后皮肤屏障功能[皮脂含量、角质层含水量及经皮水分丢失(TEWL)含量]、血清因子(IL-4、IgE)水平及生活质量评分。结果:观察组患者整体疗效较对照组显著提高(P<0.05)。治疗后观察组患者皮脂含量和角质层含水量均高于对照组,TEWL低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血清IL-4和IgE较治疗前均显著降低,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后两组皮肤病生活质量指数(DLQI)和特应性皮炎积分(SCORAD)较治疗前均显著降低,且观察组低于对照组(P<0.05)。结论:健脾祛风汤联合皮炎洗剂用于特应性皮炎效果显著,有助于保护皮肤屏障功能,减轻临床症状,改善患者生活质量。

卵清蛋白诱导的特应性皮炎小鼠模型中白细胞介素-25的作用及其调控意义

目的:探讨白细胞介素-25(interleukin-25,IL-25)对卵清蛋白(ovalbumin,OVA)诱导的特应性皮炎小鼠模型的影响,以及调控IL-25的意义。方法:将90只健康雄性6周龄无特定病原体(specific pathogen free,SPF)级BALB/c小鼠分为6组(每组15只),分别为:①皮下注射磷酸盐缓冲液(phosphate buffered saline,PBS)组(正常对照组);②皮下注射小鼠IL-25组(IL-25组);③皮下注射抗小鼠IL-25单克隆抗体组(anti-IL-25组),每日皮下注射1次×1周,间隔2周,重复每日皮下注射1次×1周,间隔2周,再重复每日皮下注射1次×1周,总共7周;④OVA致敏组(模型组);⑤OVA致敏及IL-25皮下注射组(IL-25干预致敏组);⑥OVA致敏及anti-IL-25注射组(anti-IL-25干预致敏组)。⑤⑥组在致敏过程中给予IL-25或anti-IL-25的方式同②③组。致敏期间观察比较小鼠的搔抓行为和皮肤表现,致敏结束24 h后由小鼠心脏取血,分离血清,采用酶联免疫吸附试验(enzyme linked immunosorbent assay,ELISA)检测总IgE、IL-4、IL-5、IL-13等。取致敏部位的皮肤进行苏木精-伊红(hematoxylin-eosin,HE)染色、免疫组织化学、实时PCR(real-time PCR)及Western blot检测。采用单因素(ANOVA)方差分析比较各组间各项指标的差异。结果:实验小鼠末次处理24 h后,IL-25干预致敏组的搔抓次数高于模型组,anti-IL-25干预致敏组的搔抓行为显著低于模型组;IL-25干预致敏组特应性皮炎表现、表皮增厚及真皮炎细胞浸润程度均明显重于模型组及anti-IL-25干预致敏组;IL-25干预致敏组血清IgE、IL-4、IL-5、IL-13水平显著高于模型组及anti-IL-25干预致敏组;IL-25干预致敏组CD4+T细胞在真皮层较anti-IL-25干预致敏组显著增多;IL-25干预致敏组的丝聚蛋白(filaggrin)及防御素β2(defensinβ2)蛋白水平明显低于模型组或anti-IL-25干预致敏组。结论:在OVA诱导的皮炎模型中,IL-25能够明显促进小鼠表皮屏障功能损害,加重OVA诱导的皮炎损害,拮抗IL-25可一定程度上缓解OVA诱导的皮炎损害。

度普利尤单抗治疗哮喘合并特应性共病有效性和安全性回顾性分析

目的评估度普利尤单抗治疗哮喘合并特应性共病的临床有效性及安全性。方法采用回顾性分析,纳入2020年3月至2023年10月在上海交通大学医学院附属仁济医院变态反应科接受度普利尤单抗治疗16周以上的过敏性哮喘伴特应性共病的患者。分析比较患者治疗前、后临床症状改善及安全性状况,吸入性糖皮质激素用量、肺功能、呼出气一氧化氮、相关实验室指标等变化。结果共纳入过敏性哮喘伴特应性皮炎患者21例,其中19例为传统治疗药物控制不佳者,2例奥马珠单抗治疗应答不佳而转为度普利尤单抗治疗的患者。21例患者均完成至少16周以上的治疗和随访。哮喘改善方面:与基线对比,治疗16周后患者的FeNO中位数由(40.33±26.97)ppb下降至(24.52±10.75)ppb(P<0.01);第1秒用力呼气容积占预计值%(FEV_(1)pred%)均值由(85.34%±5.82%)上升至(91.1%±11.65%)(P<0.05);吸入ICS用量由400(200,600)(μg/d)下降至0(0,100)μg/d(P<0.05);哮喘生活质量评分(AQLQ)下降(P<0.01)。治疗前嗜酸性粒细胞(eosinophils,EOS)水平与治疗后的肺功能改善呈正相关(Pearson相关系数r=0.642658,P<0.05)。共病改善方面:治疗后患者总IgE、VAS评分、特应性皮炎评分(SCORAD)、瘙痒峰值评分(NRS)、鼻结膜炎生活质量评分(RQLQ)均下降(P<0.01)。治疗期间,仅5例(5/21)出现轻度不良反应,未见药物相关严重不良反应。结论度普利尤单抗可显著改善哮喘的临床症状,降低气道炎症,提升肺功能,且不良反应轻微。

湿包疗法在成人中重度特应性皮炎及其他皮炎湿疹类皮肤病中的疗效观察

目的观察湿包疗法(WWT)在特应性皮炎及其他皮炎湿疹类皮肤病中的疗效及安全性。方法回顾分析2015年1月—2023年5月在首都医科大学附属北京友谊医院皮肤科住院期间应用WWT治疗的特应性皮炎(AD)及其他皮炎湿疹类皮肤病患者,总结WWT的疗效及不良反应。结果共收集44例患者,病种包括AD、红皮病、嗜酸性粒细胞增多性皮炎、湿疹、AD结节痒疹型、光敏性皮炎以及药疹。治疗后患者湿疹面积及严重程度指数(EASI)、研究者总体评估(IGA)、体表受累面积(BSA)、瘙痒-数字评价量表(NRS)均得到显著改善,外周血嗜酸性粒细胞水平较前下降。AD结节痒疹型组WWT应用时间显著高于AD、红皮病和湿疹组。应用0.05%卤米松乳膏进行WWT组的EASI评分下降率显著高于0.1%糠酸莫米松乳膏组和青鹏软膏组。应用0.05%卤米松乳膏进行WWT组患者治疗后IGA评分显著低于青鹏软膏组。结论WWT治疗成人中重度AD及皮炎湿疹类疾病的疗效肯定,安全性好。

度普利尤单抗治疗特应性皮炎致面部传染性软疣1例

61岁女性患者。全身红斑20余年,左侧面颊丘疹2周。3个月前患者因全身特应性皮炎反复发作20余年接受度普利尤单抗治疗,2周前左侧面颊部多发绿豆至黄豆大小肤色丘疹,其中颞部可见一花生米大小红色结节。结节组织病理示:真皮内可见呈分叶、内生性生长的结节状病灶,病灶内细胞的胞质有嗜酸性包涵体。诊断:传染性软疣;特应性皮炎(中重度)。治疗:外用院内制剂祛疣散外敷治疗疣体,并继续进行度普利尤单抗治疗特应性皮炎。